A number of other equities analysts have also commented on DVA. Wolfe Research raised Davita from a market perform rating to an outperform rating in a research note on Monday, October 23rd. Royal Bank of Canada dropped their price target on Davita from $64.00 to $60.00 and set a sector perform rating for the company in a research note on Wednesday, November 8th. Bank of America lowered their price objective on Davita from $75.00 to $66.00 and set a neutral rating for the company in a research note on Wednesday, November 8th. Robert W. Baird reaffirmed a hold rating and issued a $63.00 price objective on shares of Davita in a research note on Friday, November 10th. Finally, KeyCorp reaffirmed a hold rating on shares of Davita in a research note on Monday, November 13th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $79.30.
Davita (NYSE DVA) opened at $74.53 on Wednesday. Davita has a one year low of $52.51 and a one year high of $80.71. The company has a market capitalization of $13,479.88, a P/E ratio of 21.38 and a beta of 0.99. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.35 and a current ratio of 1.40.
In other news, insider Charles Berg sold 7,048 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $69.24, for a total value of $488,003.52. Following the completion of the sale, the insider now directly owns 5,359 shares of the company’s stock, valued at approximately $371,057.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Kent J. Thiry sold 81,800 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $68.04, for a total value of $5,565,672.00. The disclosure for this sale can be found here. Insiders sold a total of 121,509 shares of company stock valued at $8,310,388 over the last ninety days. Corporate insiders own 2.10% of the company’s stock.
Several hedge funds have recently modified their holdings of DVA. Eqis Capital Management Inc. lifted its stake in shares of Davita by 62.5% during the 3rd quarter. Eqis Capital Management Inc. now owns 7,473 shares of the company’s stock worth $444,000 after acquiring an additional 2,873 shares during the last quarter. Xact Kapitalforvaltning AB lifted its stake in shares of Davita by 22.8% during the 3rd quarter. Xact Kapitalforvaltning AB now owns 19,851 shares of the company’s stock worth $1,179,000 after acquiring an additional 3,685 shares during the last quarter. Founders Capital Management LLC lifted its stake in shares of Davita by 2.3% during the 3rd quarter. Founders Capital Management LLC now owns 95,939 shares of the company’s stock worth $5,698,000 after acquiring an additional 2,115 shares during the last quarter. Speece Thorson Capital Group Inc. lifted its stake in shares of Davita by 14.5% during the 3rd quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock worth $19,075,000 after acquiring an additional 40,667 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in shares of Davita by 14.7% during the 3rd quarter. Canada Pension Plan Investment Board now owns 444,358 shares of the company’s stock worth $26,390,000 after acquiring an additional 56,988 shares during the last quarter. 84.45% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2018/02/15/davita-dva-earns-hold-rating-from-suntrust-banks.html.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.